Selecta Biosciences
480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States
Tel: 617-923-1400
Fax: 617-924-3454
Website: http://www.selectabio.com/
Email: info@selectabio.com
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
Exchange: NASDAQ
176 articles with Selecta Biosciences
-
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
3/21/2023
Selecta Biosciences, Inc. and Sobi®, announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout.
-
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
3/21/2023
Selecta Biosciences, Inc. and Sobi®, announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout.
-
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/2/2023
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
2/23/2023
Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update.
-
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
2/7/2023
Selecta Biosciences, Inc. today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.
-
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
1/9/2023
Selecta Biosciences, Inc. and Astellas Pharma Inc. today announced an exclusive licensing and development agreement for IdeXork (Xork).
-
Selecta Biosciences Provides Business Update and Outlook for 2023
1/9/2023
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today provided a corporate update, including its roadmap for 2023.
-
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
12/14/2022
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced the selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program.
-
Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
11/28/2022
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022.
-
Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
11/7/2022
Selecta Biosciences, Inc. today announced that Company’s Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day, to be held in-person in New York, NY from November 14-15, 2022.
-
Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
11/3/2022
Selecta Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
10/27/2022
Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.
-
Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
10/11/2022
Selecta Biosciences, Inc. today announced three upcoming presentations, including one joint presentation with our partner AskBio, at the 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference.
-
Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions
9/29/2022
Selecta Biosciences, Inc. extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells.
-
Selecta Biosciences to Participate in Upcoming September 2022 Investor Conferences
9/12/2022
Selecta Biosciences, Inc.announced that Company’s Management will participate in upcoming investor conferences in September.
-
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in a fireside chat and participate virtually in one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Selecta Biosciences, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Selecta Biosciences to Participate in Upcoming Investor Conferences - Aug 01, 2022
8/1/2022
Selecta Biosciences, Inc. announced that Company’s Management will participate in upcoming investor conferences in August.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update
7/28/2022
Selecta Biosciences, Inc. today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.
-
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
7/6/2022
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate virtually in a fireside chat and in one-on-one investor meetings at the Guggenheim I&I Spotlight Series.